Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
← catalyst calendarNCT07620574 · readout in 1,381 d
Sponsored by Exelixis (industry) · EXEL — their whole pipeline →. With Bristol-Myers Squibb.
Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
5,000estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-30 | actual | When the study began enrolling |
| Primary completion | 2030-05-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-05-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cancer
- Renal Cell Carcinoma (RCC)
- Pancreatic Neuroendocrine Tumors (pNET)
- Extra-Pancreatic NET (epNET)
- Hepatocellular Carcinoma (HCC)
- Differentiated Thyroid Cancer (DTC)
- Non-Clear Cell Renal Cell Carcinoma (nccRCC)
- Colorectal Cancer
- Prostate Cancer
Interventions
- Drug: Cabozantinib — also filed as XL184, Cabometyx
- Drug: Zanzalintinib — also filed as XL092
- Drug: Atezolizumab
- Drug: Nivolumab
- Drug: Abiraterone
- Drug: Prednisone
- Drug: Enzalutamide
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Treatment Emergent Adverse Events (TEAEs)
measured Up to 4 years (until the event resolves, returns to baseline, stabilizes, a new anticancer therapy is initiated, or the participant is lost to follow-up or withdraws consent, whichever occurs first)
Permalink · EXEL's whole pipeline · Catalyst calendar · Every registered study · What changed